SC ruling on use of stem cells for autism sets a precedent for healthcare regulation, Pg11

Key Highlights:

• The Supreme Court on January 30 banned the use of stem cells as a therapy for autism, setting a precedent for regulating novel treatments.
• The verdict addresses the lack of scientific protocols, poor regulation, and commercialization in India's healthcare system.
• The court highlighted the absence of scientific evidence supporting the efficacy of stem cell therapy for autism.
• The ruling protects citizens from fraudulent and harmful misuse of expensive medical advances, particularly in stem cell therapy.

Detailed Insights:

• Stem cell therapy for autism lacks conclusive evidence due to poor methodology, inconsistent doses, and short follow-ups in clinical trials.
• India is a hub for stem cell centers claiming cures for various diseases, exploiting regulatory inaction and charging exorbitant fees.
• The National Medical Commission deems stem cell therapy as not recommended, labeling its promotion as professional misconduct.
• The Supreme Court stated that patients cannot demand unproven therapies outside clinical trials, addressing the issue of patient consent.
• The judgment's implementation faces challenges due to weak regulatory bodies and a healthcare system dominated by commerce.
• The case highlights the need for both access to proven therapies and protection from dubious ones in India's healthcare landscape.

Key Concepts Involved:

• Stem Cells: Unique unspecialized cells that can self-renew or transform into specialized cells.
• Autism: A neuro-developmental condition characterized by social communication deficits and repetitive behaviors.
• Clinical Trials: Research studies designed to evaluate the safety and effectiveness of medical treatments or interventions.